: The spread of drug-resistant tuberculosis (TB) encouraged the development of new medicines and the reappraisal of old drugs rarely used in recent years. Providing access for children with drug-resistant TB to appropriate treatments is a cornerstone of strategies to reduce the burden of TB worldwide. Aim of this perspective is to describe the availability of child-friendly medicines to treat drug-resistant TB at the global level. We showed that the development of child-friendly formulations of second-line drugs should be encouraged to promote adherence to recommended treatment regimens and consequently to increase the success rate and to prevent the development of additional mycobacterial resistances. This is even more crucial considering the long duration of anti-tubercular therapies. Importantly, companies and policy-makers are called to more efforts in facilitating their prompt availability in every contest, as drug-resistant pediatric TB is a global medical problem.

MDR-TB in children: are the same therapy options available worldwide? / Buonsenso, Danilo; Autore, Giovanni; Cusenza, Francesca; Passadore, Lucrezia; Bonanno, Francesca; Esposito, Susanna. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - (2023). [10.1016/j.ijid.2023.03.023]

MDR-TB in children: are the same therapy options available worldwide?

Autore, Giovanni;Cusenza, Francesca;Passadore, Lucrezia;Bonanno, Francesca;Esposito, Susanna
2023-01-01

Abstract

: The spread of drug-resistant tuberculosis (TB) encouraged the development of new medicines and the reappraisal of old drugs rarely used in recent years. Providing access for children with drug-resistant TB to appropriate treatments is a cornerstone of strategies to reduce the burden of TB worldwide. Aim of this perspective is to describe the availability of child-friendly medicines to treat drug-resistant TB at the global level. We showed that the development of child-friendly formulations of second-line drugs should be encouraged to promote adherence to recommended treatment regimens and consequently to increase the success rate and to prevent the development of additional mycobacterial resistances. This is even more crucial considering the long duration of anti-tubercular therapies. Importantly, companies and policy-makers are called to more efforts in facilitating their prompt availability in every contest, as drug-resistant pediatric TB is a global medical problem.
2023
MDR-TB in children: are the same therapy options available worldwide? / Buonsenso, Danilo; Autore, Giovanni; Cusenza, Francesca; Passadore, Lucrezia; Bonanno, Francesca; Esposito, Susanna. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - (2023). [10.1016/j.ijid.2023.03.023]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2941716
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact